Oncologist counseling practice and COVID-19 vaccination outcomes for patients with history of PEG-asparaginase hypersensitivity.
Sara ZarnegarCosby A StoneChristine Moore SmithLaura L HallKate E LuckGrace KooJessica H PlagerElizabeth J PhillipsDebra L FriedmanPublished in: Pediatric blood & cancer (2022)
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an effective strategy to prevent serious coronavirus disease 2019 (COVID-19) and is important for oncology patients. mRNA-based COVID-19 vaccines are contraindicated in those with a history of severe or immediate allergy to any vaccine component, including polyethylene glycol (PEG)2000. Patients with acute lymphoblastic leukemia/lymphoma receive asparaginase conjugated to PEG5000 (PEG-ASNase) and those with PEG-ASNase-associated hypersensitivity may be unnecessarily excluded from receiving mRNA COVID-19 vaccines. We, therefore, surveyed oncologists on COVID-19 vaccine counseling practice and vaccination outcomes in COVID-19 vaccination-eligible patients and show safe receipt of mRNA vaccines despite PEG-ASNase hypersensitivity.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- drug delivery
- acute lymphoblastic leukemia
- newly diagnosed
- end stage renal disease
- ejection fraction
- healthcare
- primary care
- drug induced
- palliative care
- early onset
- photodynamic therapy
- binding protein
- diffuse large b cell lymphoma
- smoking cessation
- adipose tissue
- skeletal muscle
- metabolic syndrome
- human immunodeficiency virus
- infectious diseases
- advanced cancer